4//SEC Filing
Hefti Franz 4
Accession 0001209191-20-018133
CIK 0001714798other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 4:53 PM ET
Size
5.6 KB
Accession
0001209191-20-018133
Insider Transaction Report
Form 4
Hefti Franz
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-19+62,200→ 62,200 totalExercise: $16.91Exp: 2030-02-19→ Common Stock (62,200 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option vest and become exercisable on February 19, 2021 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
Documents
Issuer
Prevail Therapeutics Inc.
CIK 0001714798
Entity typeother
Related Parties
1- filerCIK 0001735529
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 4:53 PM ET
- Size
- 5.6 KB